Based on these findings, a maternal HFD induces fetal origins of NASH/HCC via hypoxia, and HORMAD1 is a potential therapeutic target for NASH/HCC. This evidence concerns the gene HORMAD1 and metabolic dysfunction-associated steatohepatitis.